Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CooperSurgical predicts $100 million turnover within two years

This article was originally published in Clinica

Executive Summary

The Cooper Companies' women's health business, CooperSurgical, had sales of $13 million in the quarter and $26 million over six months. The division had operating income of $2.3 million and $4.1 million for the same periods. The Lake Forest, California company says annual revenue is approaching $60 million and this could increase to $100 million within two years. Its operating margins are expected to approach 20% by the end of the fiscal year. The company has recently added a range of new products through acquisition or marketing alliances. These include products in the MedaSonics foetal monitor line, which are manufactured by Analogic under an OEM arrangement; a range of bone measurement systems for the evaluation of osteoporosis - CooperSurgical markets these under an agreement with Norland Medical Systems; and the LuMax pro fibre optic cystometry system, used to diagnose the cause of female incontinence. It bought LuMax from Medamicus in April.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT071517

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel